共 50 条
Progress and controversies in neoadjuvant therapy
被引:0
|作者:
Edwin M. Posadas
Robert A. Figlin
机构:
[1] Urologic Oncology Program,
[2] Samuel Oschin Comprehensive Cancer Institute,undefined
[3] Cedars–Sinai Medical Center,undefined
来源:
Nature Reviews Urology
|
2014年
/
11卷
关键词:
D O I:
暂无
中图分类号:
学科分类号:
摘要:
Use of clinically active agents, such as kinase inhibitors, before nephrectomy is safe and feasible and can decrease the size of primary tumours, enabling optimization of the surgical approach. However, the overall clinical benefit of the neoadjuvant use of toxic drugs, such as axitinib, has not yet been demonstrated.
引用
收藏
页码:254 / 256
页数:2
相关论文